Spectris (SXS) M&A Announcement summary
Event summary combining transcript, slides, and related documents.
M&A Announcement summary
3 Feb, 2026Deal rationale and strategic fit
Acquisition creates a global leader in particle characterisation for advanced materials analysis by combining Micromeritics with Malvern Panalytical, offering a fully integrated and differentiated product suite.
Highly complementary portfolios strengthen presence in clean tech and industrial tech markets, leveraging geographic strengths and enabling end-to-end customer workflows.
Provides customers with the broadest suite of integrated instruments, improving workflow efficiency and enabling deeper insights.
Micromeritics is a critical enabler in high-growth end markets such as advanced batteries, carbon capture, and hydrogen.
The acquisition is seen as a strong cultural and operational fit, with leadership continuity and opportunities for talent development.
Financial terms and conditions
Upfront consideration of $630 million, plus up to $53 million deferred based on 2024 and 2025 performance metrics.
Implied multiple of 18x 2024 expected EBITDA ($35 million), dropping below 14x with $12 million in run-rate cost synergies.
Deal funded through a mix of existing cash and new external debt; leverage expected to return to around 1x EBITDA by end of 2025.
Interest on new debt expected in the 5%-6% range.
Earn-out split roughly 50/50 between 2024 and 2025 performance, payable in early 2025 and 2026.
Synergies and expected cost savings
Annual run-rate cost synergies of $12 million expected, with additional revenue synergies anticipated to match cost synergies.
Synergies to be realized through economies of scale in sourcing, go-to-market alignment, sales, marketing, and back-office integration.
Most synergies targeted for realization during 2025, with run-rate benefits expected by year-end 2025.
Significant cross-selling opportunities, as about 60% of customers use only one provider's instruments.
Enhanced aftermarket and service revenue potential by aligning Micromeritics' coverage with Malvern Panalytical's levels.
Latest events from Spectris
- Q4 order growth, acquisitions, and cost actions set up strong profit recovery for 2025.SXS
Q4 20243 Feb 2026 - Acquisition expands into handheld tech, targeting strong growth and $6m in synergies.SXS
M&A Announcement3 Feb 2026 - Full-year profit now expected at or just below the low end of consensus due to ERP and market headwinds.SXS
Trading Update3 Feb 2026 - H1 sales and profit fell, but strong cash, order book, and acquisitions support future growth.SXS
H1 20242 Feb 2026 - Drives growth and innovation in contamination monitoring for semiconductors and life sciences.SXS
Status Update31 Jan 2026 - Q3 sales fell 13% as market recovery lags, but cost actions and acquisitions support future growth.SXS
Q3 2024 TU17 Jan 2026 - Drives growth in premium gas analysis through innovation, sustainability, and operational excellence.SXS
Status Update11 Jan 2026 - Acquisitions and cost actions offset Q1 softness, supporting 2025 margin growth guidance.SXS
Q1 2025 TU24 Dec 2025 - Sales and profit rose, cash conversion was strong, and acquisition synergies boosted outlook.SXS
Q2 202523 Nov 2025